Chronic Kidney Disease and Atrial Fibrillation: A Contemporary Overview

Area of Science:

• Nephrology
• Cardiology
• Clinical Medicine

Background:

• Chronic kidney disease (CKD) significantly increases cardiovascular risks, including myocardial infarction, heart failure, and stroke.
• Atrial fibrillation (AF), a common arrhythmia, elevates stroke and mortality risk, with higher prevalence and incidence observed in patients with renal impairment.
• Worsening renal function correlates with an increased risk of developing AF, suggesting a strong link between kidney health and cardiac rhythm.

Purpose of the Study:

• To review the association between CKD and AF, including potential underlying mechanisms.
• To evaluate the current understanding of antithrombotic therapy's safety and efficacy in CKD patients with AF.
• To identify knowledge gaps and the need for further research regarding anticoagulation in this population.

Main Methods:

• Literature review and synthesis of existing studies on CKD, AF, and antithrombotic therapy.
• Analysis of potential pathophysiological links between renal impairment and atrial fibrillation.
• Examination of data on the efficacy and safety of anticoagulation in CKD patients, considering varying degrees of renal function.

Main Results:

• AF is more prevalent and incident in CKD patients, with risk increasing as kidney function declines.
• Mechanisms linking CKD and AF may involve sympathetic overactivity, renin-angiotensin-aldosterone system activation, and cardiac remodeling.
• While vitamin K antagonists show promise in mild-to-moderate CKD, the risk-benefit of anticoagulation in advanced renal failure and dialysis remains unclear.

Conclusions:

• AF poses a significant risk for stroke and mortality in CKD patients, mirroring general population trends.
• The safety and efficacy of antithrombotic treatments in CKD patients with AF are not well-established, particularly in advanced stages.
• Prospective randomized trials are essential to determine the optimal antithrombotic strategy for reducing stroke risk in patients with comorbid AF and CKD.